The vaccine and biotechnology company Abera Bioscience reported, as planned, no revenue in the fourth quarter. The operating result showed a loss compared with the previous period's profit.The operating result was -SEK 8.9 million (0.2). The result both before and after tax was -SEK 8.8 million (0.2). Earnings per share amounted to -SEK 0.47 (0.01). Cash flow from operating activities amounted to -SEK 8.7 million (0.2). Cash and cash equivalents amounted to SEK 23.5 million (6.1)."The development of our influenza vaccine candidate is continuing according to plan. In 2025, we have presented several very promising study results and are now conducting additional studies. During the spring, we plan to carry out several studies in ferret models with high relevance for humans, which will provide both broader and deeper data and enable the next step toward clinical development also for the influenza program," comments CEO Maria Alriksson.Abera Bioscience, SEK millionQ4 2025Q4 2024Net sales00Operating result-8.90.2Result before tax-8.80.2Net result-8.80.2Earnings per share, SEK-0.470.01Cash flow from operating activities-8.70.2Cash and cash equivalents23.56.1